{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:58:44Z","timestamp":1791932324808,"version":"4.3.4"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Viral infections lead to alarmin release and elicit potent cytotoxic effector T lymphocyte (CTL\n                    <jats:sup>eff<\/jats:sup>\n                    ) responses. Conversely, the induction of protective tumour-specific CTL\n                    <jats:sup>eff<\/jats:sup>\n                    and their recruitment into the tumour remain challenging tasks. Here we show that lymphocytic choriomeningitis virus (LCMV) can be engineered to serve as a replication competent, stably-attenuated immunotherapy vector (artLCMV). artLCMV delivers tumour-associated antigens to dendritic cells for efficient CTL priming. Unlike replication-deficient vectors, artLCMV targets also lymphoid tissue stroma cells expressing the alarmin interleukin-33. By triggering interleukin-33 signals, artLCMV elicits CTL\n                    <jats:sup>eff<\/jats:sup>\n                    responses of higher magnitude and functionality than those induced by replication-deficient vectors. Superior anti-tumour efficacy of artLCMV immunotherapy depends on interleukin-33 signalling, and a massive CTL\n                    <jats:sup>eff<\/jats:sup>\n                    influx triggers an inflammatory conversion of the tumour microenvironment. Our observations suggest that replicating viral delivery systems can release alarmins for improved anti-tumour efficacy. These mechanistic insights may outweigh safety concerns around replicating viral vectors in cancer immunotherapy.\n                  <\/jats:p>","DOI":"10.1038\/ncomms15327","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T06:20:21Z","timestamp":1495779621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy"],"prefix":"10.1038","volume":"8","author":[{"given":"Sandra M.","family":"Kallert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Darbre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weldy V.","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Kreutzfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kreuzaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Favre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kreppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"L\u00f6hning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv A.","family":"Luther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Zippelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Merkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1594-3189","authenticated-orcid":false,"given":"Daniel D.","family":"Pinschewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,26]]},"reference":[{"key":"BFncomms15327_CR1","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"BFncomms15327_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"BFncomms15327_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nm.4015","volume":"22","author":"CA Klebanoff","year":"2016","unstructured":"Klebanoff, C. A., Rosenberg, S. A. & Restifo, N. P. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat. Med. 22, 26\u201336 (2016).","journal-title":"Nat. Med."},{"key":"BFncomms15327_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411\u2013422 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFncomms15327_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","volume":"17","author":"JF Vansteenkiste","year":"2016","unstructured":"Vansteenkiste, J. F. et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 17, 822\u2013835 (2016).","journal-title":"Lancet Oncol."},{"key":"BFncomms15327_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","volume":"15","author":"C Butts","year":"2014","unstructured":"Butts, C. et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 59\u201368 (2014).","journal-title":"Lancet Oncol."},{"key":"BFncomms15327_CR7","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMoa051424","volume":"353","author":"F Pages","year":"2005","unstructured":"Pages, F. et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654\u20132666 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFncomms15327_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237\u2013251 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"BFncomms15327_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203\u2013213 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFncomms15327_CR10","doi-asserted-by":"publisher","first-page":"282ra248","DOI":"10.1126\/scitranslmed.aaa3700","volume":"7","author":"SA Fuertes Marraco","year":"2015","unstructured":"Fuertes Marraco, S. A. et al. Long-lasting stem cell-like memory CD8+ T cells with a naive-like profile upon yellow fever vaccination. Sci. Transl. Med. 7, 282ra248 (2015).","journal-title":"Sci. Transl. Med."},{"key":"BFncomms15327_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1126\/science.1215418","volume":"335","author":"WV Bonilla","year":"2012","unstructured":"Bonilla, W. V. et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science 335, 984\u2013989 (2012).","journal-title":"Science"},{"key":"BFncomms15327_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1084\/jem.20051720","volume":"203","author":"T Querec","year":"2006","unstructured":"Querec, T. et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203, 413\u2013424 (2006).","journal-title":"J. Exp. Med."},{"key":"BFncomms15327_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909\u2013915 (2004).","journal-title":"Nat. Med."},{"key":"BFncomms15327_CR14","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014\u20131022 (2013).","journal-title":"Nat. Immunol."},{"key":"BFncomms15327_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74\u201380 (2015).","journal-title":"Science"},{"key":"BFncomms15327_CR16","doi-asserted-by":"publisher","first-page":"226ra232","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra232 (2014).","journal-title":"Sci. Transl. Med."},{"key":"BFncomms15327_CR17","first-page":"1","volume":"263","author":"RM Zinkernagel","year":"2002","unstructured":"Zinkernagel, R. M. Lymphocytic choriomeningitis virus and immunology. Curr. Top. Microbiol. Immunol. 263, 1\u20135 (2002).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"BFncomms15327_CR18","first-page":"157","volume":"1","author":"HE Webb","year":"1975","unstructured":"Webb, H. E., Molomut, N., Padnos, M. & Wetherley-Mein, G. The treatment of 18 cases of malignant disease with an arenavirus. Clin. Oncol. 1, 157\u2013169 (1975).","journal-title":"Clin. Oncol."},{"key":"BFncomms15327_CR19","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/nm0896-906","volume":"2","author":"MF Callan","year":"1996","unstructured":"Callan, M. F. et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat. Med. 2, 906\u2013911 (1996).","journal-title":"Nat. Med."},{"key":"BFncomms15327_CR20","doi-asserted-by":"publisher","first-page":"11770","DOI":"10.1128\/JVI.05477-11","volume":"85","author":"MF Kotturi","year":"2011","unstructured":"Kotturi, M. F. et al. Human CD8(+) and CD4(+) T cell memory to lymphocytic choriomeningitis virus infection. J. Virol. 85, 11770\u201311780 (2011).","journal-title":"J. Virol."},{"key":"BFncomms15327_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1537-2995.2007.01081.x","volume":"47","author":"X de Lamballerie","year":"2007","unstructured":"de Lamballerie, X., Fulhorst, C. F. & Charrel, R. N. Prevalence of antibodies to lymphocytic choriomeningitis virus in blood donors in southeastern France. Transfusion 47, 172\u2013173 (2007).","journal-title":"Transfusion"},{"key":"BFncomms15327_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/jmv.1890380107","volume":"38","author":"CB Stephensen","year":"1992","unstructured":"Stephensen, C. B. et al. Prevalence of serum antibodies against lymphocytic choriomeningitis virus in selected populations from two US cities. J. Med. Virol. 38, 27\u201331 (1992).","journal-title":"J. Med. Virol."},{"key":"BFncomms15327_CR23","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1073\/pnas.1418549112","volume":"112","author":"C Baumann","year":"2015","unstructured":"Baumann, C. et al. T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc. Natl Acad. Sci. USA 112, 4056\u20134061 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms15327_CR24","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1182\/blood-2014-10-606830","volume":"125","author":"DK Reichenbach","year":"2015","unstructured":"Reichenbach, D. K. et al. The IL-33\/ST2 axis augments effector T-cell responses during acute GVHD. Blood 125, 3183\u20133192 (2015).","journal-title":"Blood"},{"key":"BFncomms15327_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.it.2016.03.007","volume":"37","author":"M Peine","year":"2016","unstructured":"Peine, M., Marek, R. M. & Lohning, M. IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol. 37, 321\u2013333 (2016).","journal-title":"Trends Immunol."},{"key":"BFncomms15327_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nm.2104","volume":"16","author":"L Flatz","year":"2010","unstructured":"Flatz, L. et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8(+) T cell immunity. Nat. Med. 16, 339\u2013345 (2010).","journal-title":"Nat. Med."},{"key":"BFncomms15327_CR27","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1073\/pnas.0600652103","volume":"103","author":"L Flatz","year":"2006","unstructured":"Flatz, L., Bergthaler, A., de la Torre, J. C. & Pinschewer, D. D. Recovery of an arenavirus entirely from RNA polymerase I\/II-driven cDNA. Proc. Natl Acad. Sci. USA 103, 4663\u20134668 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms15327_CR28","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.0900088106","volume":"106","author":"SF Emonet","year":"2009","unstructured":"Emonet, S. F., Garidou, L., McGavern, D. B. & de la Torre, J. C. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc. Natl Acad. Sci. USA 106, 3473\u20133478 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms15327_CR29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3892\/ijmm.2013.1395","volume":"32","author":"A Hyvarinen","year":"2013","unstructured":"Hyvarinen, A., Yongabi, F., Makinen, K., Wahlfors, J. & Pellinen, R. Recombination of replicon and helper RNAs and the emergence of propagation-competent vectors upon Sindbis virus vector production. Int. J. Mol. Med. 32, 410\u2013422 (2013).","journal-title":"Int. J. Mol. Med."},{"key":"BFncomms15327_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1126\/science.1068284","volume":"296","author":"O Kew","year":"2002","unstructured":"Kew, O. et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296, 356\u2013359 (2002).","journal-title":"Science"},{"key":"BFncomms15327_CR31","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1099\/vir.0.19277-0","volume":"84","author":"ER Chare","year":"2003","unstructured":"Chare, E. R., Gould, E. A. & Holmes, E. C. Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses. J. Gen. Virol. 84, 2691\u20132703 (2003).","journal-title":"J. Gen. Virol."},{"key":"BFncomms15327_CR32","doi-asserted-by":"publisher","first-page":"e1004900","DOI":"10.1371\/journal.ppat.1004900","volume":"11","author":"MD Stenglein","year":"2015","unstructured":"Stenglein, M. D. et al. Widespread recombination, reassortment, and transmission of unbalanced compound viral genotypes in natural arenavirus infections. PLoS Pathog. 11, e1004900 (2015).","journal-title":"PLoS Pathog."},{"key":"BFncomms15327_CR33","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1128\/JVI.77.2.1184-1194.2003","volume":"77","author":"M Perez","year":"2003","unstructured":"Perez, M. & de la Torre, J. C. Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 77, 1184\u20131194 (2003).","journal-title":"J. Virol."},{"key":"BFncomms15327_CR34","doi-asserted-by":"publisher","first-page":"7442","DOI":"10.1016\/j.vaccine.2009.05.095","volume":"27","author":"M Suter","year":"2009","unstructured":"Suter, M. et al. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine 27, 7442\u20137450 (2009).","journal-title":"Vaccine"},{"key":"BFncomms15327_CR35","doi-asserted-by":"publisher","first-page":"7928","DOI":"10.1128\/JVI.00486-11","volume":"85","author":"DL Popkin","year":"2011","unstructured":"Popkin, D. L. et al. Expanded potential for recombinant trisegmented lymphocytic choriomeningitis viruses: protein production, antibody production, and in vivo assessment of biological function of genes of interest. J. Virol. 85, 7928\u20137932 (2011).","journal-title":"J. Virol."},{"key":"BFncomms15327_CR36","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1128\/JVI.76.8.3810-3818.2002","volume":"76","author":"WV Bonilla","year":"2002","unstructured":"Bonilla, W. V. et al. Effects of promyelocytic leukemia protein on virus-host balance. J. Virol. 76, 3810\u20133818 (2002).","journal-title":"J. Virol."},{"key":"BFncomms15327_CR37","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1128\/JVI.01617-08","volume":"83","author":"Z Waibler","year":"2009","unstructured":"Waibler, Z. et al. Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J. Virol. 83, 1563\u20131571 (2009).","journal-title":"J. Virol."},{"key":"BFncomms15327_CR38","doi-asserted-by":"publisher","first-page":"e1005276","DOI":"10.1371\/journal.ppat.1005276","volume":"11","author":"R Sommerstein","year":"2015","unstructured":"Sommerstein, R. et al. Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS Pathog. 11, e1005276 (2015).","journal-title":"PLoS Pathog."},{"key":"BFncomms15327_CR39","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/mt.2008.141","volume":"16","author":"R Schirmbeck","year":"2008","unstructured":"Schirmbeck, R., Reimann, J., Kochanek, S. & Kreppel, F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol. Ther. 16, 1609\u20131616 (2008).","journal-title":"Mol. Ther."},{"key":"BFncomms15327_CR40","doi-asserted-by":"publisher","first-page":"15430","DOI":"10.1073\/pnas.0702579104","volume":"104","author":"SN Mueller","year":"2007","unstructured":"Mueller, S. N. et al. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc. Natl Acad. Sci. USA 104, 15430\u201315435 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms15327_CR41","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293\u201312297 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms15327_CR42","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/bjc.2015.290","volume":"113","author":"JY Liu","year":"2015","unstructured":"Liu, J. Y. et al. CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma. Br. J. Cancer 113, 747\u2013755 (2015).","journal-title":"Br. J. Cancer"},{"key":"BFncomms15327_CR43","doi-asserted-by":"crossref","first-page":"24978","DOI":"10.18632\/oncotarget.4617","volume":"6","author":"J Liu","year":"2015","unstructured":"Liu, J. et al. Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma. Oncotarget 6, 24978\u201324989 (2015).","journal-title":"Oncotarget"},{"key":"BFncomms15327_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng, D. et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249\u2013253 (2015).","journal-title":"Nature"},{"key":"BFncomms15327_CR45","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1128\/JVI.02192-06","volume":"81","author":"J Zhu","year":"2007","unstructured":"Zhu, J., Huang, X. & Yang, Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J. Virol. 81, 3170\u20133180 (2007).","journal-title":"J. Virol."},{"key":"BFncomms15327_CR46","doi-asserted-by":"publisher","first-page":"e1000480","DOI":"10.1371\/journal.ppat.1000480","volume":"5","author":"J Delaloye","year":"2009","unstructured":"Delaloye, J. et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 5, e1000480 (2009).","journal-title":"PLoS Pathog."},{"key":"BFncomms15327_CR47","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ni.1605","volume":"9","author":"E Scandella","year":"2008","unstructured":"Scandella, E. et al. Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone. Nat. Immunol. 9, 667\u2013675 (2008).","journal-title":"Nat. Immunol."},{"key":"BFncomms15327_CR48","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","volume":"386","author":"AM Henao-Restrepo","year":"2015","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857\u2013866 (2015).","journal-title":"Lancet"},{"key":"BFncomms15327_CR49","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","volume":"3","author":"F Spertini","year":"2015","unstructured":"Spertini, F. et al. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir. Med. 3, 953\u2013962 (2015).","journal-title":"Lancet Respir. Med."},{"key":"BFncomms15327_CR50","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature12519","volume":"502","author":"SG Hansen","year":"2013","unstructured":"Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100\u2013104 (2013).","journal-title":"Nature"},{"key":"BFncomms15327_CR51","doi-asserted-by":"publisher","first-page":"7760","DOI":"10.1128\/JVI.00599-12","volume":"86","author":"L Flatz","year":"2012","unstructured":"Flatz, L. et al. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J. Virol. 86, 7760\u20137770 (2012).","journal-title":"J. Virol."},{"key":"BFncomms15327_CR52","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"BFncomms15327_CR53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231\u2013235 (2015).","journal-title":"Nature"},{"key":"BFncomms15327_CR54","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","volume":"6","author":"GP Dunn","year":"2006","unstructured":"Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836\u2013848 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"BFncomms15327_CR55","first-page":"239","volume":"263","author":"DA Enria","year":"2002","unstructured":"Enria, D. A. & Barrera Oro, J. G. Junin virus vaccines. Curr. Top. Microbiol. Immunol. 263, 239\u2013261 (2002).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"BFncomms15327_CR56","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/emboj\/21.6.1497","volume":"21","author":"A Plyusnin","year":"2002","unstructured":"Plyusnin, A., Kukkonen, S. K., Plyusnina, A., Vapalahti, O. & Vaheri, A. Transfection-mediated generation of functionally competent Tula hantavirus with recombinant S RNA segment. EMBO J. 21, 1497\u20131503 (2002).","journal-title":"EMBO J."},{"key":"BFncomms15327_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"BFncomms15327_CR58","doi-asserted-by":"publisher","first-page":"11734","DOI":"10.1128\/JVI.01613-15","volume":"89","author":"S Darbre","year":"2015","unstructured":"Darbre, S. et al. The nucleoprotein is required for lymphocytic choriomeningitis virus-based vaccine vector immunogenicity. J. Virol. 89, 11734\u201311738 (2015).","journal-title":"J. Virol."},{"key":"BFncomms15327_CR59","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.4049\/jimmunol.164.2.1125","volume":"164","author":"D Valmori","year":"2000","unstructured":"Valmori, D. et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J. Immunol. 164, 1125\u20131131 (2000).","journal-title":"J. Immunol."},{"key":"BFncomms15327_CR60","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.4049\/jimmunol.160.10.4859","volume":"160","author":"LC Anton","year":"1998","unstructured":"Anton, L. C. et al. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J. Immunol. 160, 4859\u20134868 (1998).","journal-title":"J. Immunol."},{"key":"BFncomms15327_CR61","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/sj.mt.6300306","volume":"16","author":"A Wortmann","year":"2008","unstructured":"Wortmann, A. et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16, 154\u2013162 (2008).","journal-title":"Mol. Ther."},{"key":"BFncomms15327_CR62","doi-asserted-by":"publisher","first-page":"18581","DOI":"10.1073\/pnas.1003059107","volume":"107","author":"K Oboki","year":"2010","unstructured":"Oboki, K. et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl Acad. Sci. USA 107, 18581\u201318586 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms15327_CR63","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1128\/JVI.73.6.4748-4754.1999","volume":"73","author":"P Grob","year":"1999","unstructured":"Grob, P. et al. Role of the individual interferon systems and specific immunity in mice in controlling systemic dissemination of attenuated pseudorabies virus infection. J. Virol. 73, 4748\u20134754 (1999).","journal-title":"J. Virol."},{"key":"BFncomms15327_CR64","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1084\/jem.191.6.1069","volume":"191","author":"MJ Townsend","year":"2000","unstructured":"Townsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E. & McKenzie, A. N. T1\/ST2-deficient mice demonstrate the importance of T1\/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191, 1069\u20131076 (2000).","journal-title":"J. Exp. Med."},{"key":"BFncomms15327_CR65","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0960-9822(06)00059-5","volume":"7","author":"M Lewandoski","year":"1997","unstructured":"Lewandoski, M., Wassarman, K. M. & Martin, G. R. Zp3-cre, a transgenic mouse line for the activation or inactivation of loxP-flanked target genes specifically in the female germ line. Curr. Biol. 7, 148\u2013151 (1997).","journal-title":"Curr. Biol."},{"key":"BFncomms15327_CR66","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","volume":"190","author":"KM Quinn","year":"2013","unstructured":"Quinn, K. M. et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J. Immunol. 190, 2720\u20132735 (2013).","journal-title":"J. Immunol."},{"key":"BFncomms15327_CR67","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1084\/jem.148.2.534","volume":"148","author":"PC Doherty","year":"1978","unstructured":"Doherty, P. C., Biddison, W. E., Bennink, J. R. & Knowles, B. B. Cytotoxic T-cell responses in mice infected with influenza and vaccinia viruses vary in magnitude with H-2 genotype. J. Exp. Med. 148, 534\u2013543 (1978).","journal-title":"J. Exp. Med."},{"key":"BFncomms15327_CR68","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1084\/jem.20132528","volume":"211","author":"N Fasnacht","year":"2014","unstructured":"Fasnacht, N. et al. Specific fibroblastic niches in secondary lymphoid organs orchestrate distinct Notch-regulated immune responses. J. Exp. Med. 211, 2265\u20132279 (2014).","journal-title":"J. Exp. Med."},{"key":"BFncomms15327_CR69","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1084\/jem.162.6.2125","volume":"162","author":"RM Zinkernagel","year":"1985","unstructured":"Zinkernagel, R. M., Leist, T., Hengartner, H. & Althage, A. Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction, and all three are regulated by H-2D. J. Exp. Med. 162, 2125\u20132141 (1985).","journal-title":"J. Exp. Med."},{"key":"BFncomms15327_CR70","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jim.2012.06.005","volume":"382","author":"F Duan","year":"2012","unstructured":"Duan, F. et al. Area under the curve as a tool to measure kinetics of tumor growth in experimental animals. J. Immunol. Methods 382, 224\u2013228 (2012).","journal-title":"J. Immunol. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms15327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms15327","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncomms15327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms15327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T15:18:34Z","timestamp":1692803914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms15327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,26]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,8,14]]}},"alternative-id":["BFncomms15327"],"URL":"https:\/\/doi.org\/10.1038\/ncomms15327","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,26]]},"assertion":[{"value":"2 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.D.P. is a shareholder and also a consultant to Hookipa Biotech AG commercializing arenavirus-based vector technology. S.M.K., S.D., MarK, N.P., D.M. and D.D.P. are listed as inventors on a patent entitled \u2018Tri-segmented arenaviruses as vaccine vectors\u2019 (application number PCT\/EP2015\/076458) describing artLCMV-based vector technology. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15327"}}